Cymabay Therapeutics Inc (CBAY)

$14.64

-0.77

(-5%)▲

Market is closed - opens 7 PM, 21 Sep 2023

Insights on Cymabay Therapeutics Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 176.0% return, outperforming this stock by 37.1%

Performance

  • $14.63
    $15.74
    $14.64
    downward going graph

    0.07%

    Downside

    Day's Volatility :7.05%

    Upside

    6.99%

    downward going graph
  • $3.16
    $18.20
    $14.64
    downward going graph

    78.42%

    Downside

    52 Weeks Volatility :82.64%

    Upside

    19.56%

    downward going graph

Returns

PeriodCymabay Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
73.87%
0.0%
0.0%
6 Months
63.39%
3.0%
-0.5%
1 Year
312.03%
7.2%
0.4%
3 Years
138.91%
27.5%
19.1%

Highlights

Market Capitalization
1.6B
Book Value
$1.11
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.88
PEG Ratio
0.0
Wall Street Target Price
22.17
Profit Margin
-260.27%
Operating Margin TTM
-231.54%
Return On Assets TTM
-22.2%
Return On Equity TTM
-84.59%
Revenue TTM
31.0M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-41.6M
EBITDA
-71.0M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.93
EPS Estimate Next Year
-1.35
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Cymabay Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 51.43%

Current $14.64
Target $22.17

Technicals Summary

Sell

Neutral

Buy

Cymabay Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
18.06%
63.39%
312.03%
138.91%
35.29%
Moderna, Inc.
Moderna, Inc.
-3.91%
-29.82%
-15.12%
54.11%
473.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.9%
10.13%
22.22%
50.58%
114.4%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
29.29%
91.93%
176.03%
299.56%
Seagen, Inc.
Seagen, Inc.
7.77%
4.2%
47.16%
16.48%
167.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.14%
18.37%
27.77%
35.7%
98.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
NA
NA
0.0
-0.93
-0.85
-0.22
0.0
1.11
Moderna, Inc.
Moderna, Inc.
35.66
35.66
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.39
22.39
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.6
43.6
2.03
3.3
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.75
27.75
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
Buy
$1.6B
35.29%
NA
-260.27%
Moderna, Inc.
Moderna, Inc.
Buy
$39.6B
473.87%
35.66
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.8B
114.4%
22.39
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$834.9B
299.56%
43.6
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
167.89%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$92.5B
98.94%
27.75
35.4%

Institutional Holdings

  • venBio Select Advisor LLC

    10.49%

  • HHG PLC

    7.89%

  • BlackRock Inc

    7.65%

  • Vanguard Group Inc

    5.25%

  • Octagon Capital Advisors LP

    4.66%

  • Adage Capital Partners Gp LLC

    4.48%

Corporate Announcements

  • Cymabay Therapeutics Inc Earnings

    Cymabay Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

Organization
Cymabay Therapeutics Inc
Employees
60
CEO
Mr. Sujal A. Shah
Industry
Health Technology

Discover More

FAQs